FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Home
/
update
/
details

Bayer and MOMA Therapeutics Partner to Advance Precision Oncology Therapies

NextEdge Admin

09 Oct 2024

1 min 48 sec

MOMA Therapeutics,precision therapeutics

Bayer and MOMA Therapeutics, Inc., a clinical-stage biopharmaceutical company, have entered into a collaboration to develop and commercialize a small molecule oncology program based on MOMA’s proprietary KNOMATIC™ platform. This platform integrates deep structural insights with advanced hit-finding technologies and computation-enabled lead optimization, targeting highly dynamic proteins that play critical roles in disease progression.

Under the agreement, Bayer will lead further preclinical, development, and commercial activities. The partnership reflects Bayer’s commitment to precision medicine, with the goal of accelerating the development of innovative cancer therapies. Juergen Eckhardt, Head of Business Development at Bayer’s Pharmaceuticals Division, highlighted the collaboration's potential to address unmet needs in oncology.

MOMA Therapeutics will receive an upfront payment, along with potential milestone payments and tiered royalties. Asit Parikh, CEO of MOMA, expressed excitement about the partnership, emphasizing the KNOMATIC™ platform’s power and potential in targeting disease-relevant proteins. Financial details of the collaboration were not disclosed.

MOMA Therapeutics focuses on targeting dynamic proteins that contribute to human diseases using its KNOMATIC™ platform, aiming to develop precision therapeutics for genetically validated targets with high clinical translation potential.